Schwartz P E, Chambers J T, Taylor K J, Pellerito J, Hammers L, Cole L A, Yang-Feng T L, Smith P, Mayne S T, Makuch R
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510.
Yale J Biol Med. 1991 Nov-Dec;64(6):573-82.
Eighty-four women at high risk for ovarian cancer by having first-degree relatives with epithelial ovarian cancer participated in a newly established, early ovarian cancer detection program at Yale University. Participants were to be evaluated with physical examinations and circulating tumor markers at entry and every six months thereafter. Endovaginal ultrasound and color Doppler flow studies were to be performed at three and nine months following entry into the program. In addition, women were encouraged to follow American Cancer Society guidelines for mammography. Stool was checked for occult blood. Endometrial sampling was offered to post-menopausal women. No participant has developed an ovarian cancer since entering the program. One woman has been diagnosed to have breast cancer. False-positive levels of circulating tumor markers (CA 125, 4/84 [4.8 percent]; lipid-associated sialic acid in plasma, 13/84 [15.5 percent]; NB/70K, 4/84 [4.8 percent]; and urinary gonadotropin fragment, 1/65 [1.5 percent]) were observed on entry into the program. Low resistive indices (less than 0.5) were documented in 8/91 (8.8 percent) ovaries studied by the color Doppler flow technique. One participant underwent a laparotomy based on a false-positive endovaginal ultrasound examination. Tests now being employed in community practice have a high likelihood of being associated with false-positive results. Therapeutic interventions based on isolated abnormal tumor markers or ultrasound studies obtained from women with family histories of ovarian cancer may lead to inappropriate surgery. It is necessary for cancer centers to develop expertise in ovarian cancer detection techniques to advise physicians in their geographic areas appropriately about the significance of the abnormal screening test.
84名因有上皮性卵巢癌一级亲属而处于卵巢癌高风险的女性参与了耶鲁大学新设立的早期卵巢癌检测项目。参与者在项目开始时以及此后每六个月接受体格检查和循环肿瘤标志物评估。在进入项目后的三个月和九个月进行经阴道超声和彩色多普勒血流研究。此外,鼓励女性遵循美国癌症协会的乳房X光检查指南。检查粪便潜血。为绝经后女性提供子宫内膜取样。自进入该项目以来,没有参与者患卵巢癌。一名女性被诊断患有乳腺癌。在进入项目时观察到循环肿瘤标志物的假阳性水平(CA 125,4/84 [4.8%];血浆脂质相关唾液酸,13/84 [15.5%];NB/70K,4/84 [4.8%];尿促性腺激素片段,1/65 [1.5%])。通过彩色多普勒血流技术研究的91个卵巢中,有8个(8.8%)记录到低阻力指数(小于0.5)。一名参与者因经阴道超声检查假阳性而接受了剖腹手术。目前在社区实践中使用的检测方法很可能与假阳性结果相关。基于从有卵巢癌家族史的女性中获得的孤立异常肿瘤标志物或超声研究进行的治疗干预可能导致不适当的手术。癌症中心有必要在卵巢癌检测技术方面发展专业知识,以便就异常筛查试验的意义向其所在地理区域的医生提供适当建议。